Biocon forecasts stronger second half of FY27 with multiple growth drivers despite Q2 profit decline

Biocon anticipates a robust second half of FY27, supported by several key product launches and increasing insulin sales. The company noted a 52% decline in consolidated net profit, attributed to delayed shipments affecting quarterly revenue. Ustekinumab and Aflibercept biosimilars are projected to…

Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.